Abstract
Breast carcinomas are divided into two major groups: carcinomas in situ and invasive carcinomas. Carcinomas in situ are defined as a proliferation of malignant epithelial cells confined to the ductal acinar system of the breast, with no evidence of stromal invasion. In contrast, invasive carcinomas are those in which tumor cells invade tissues adjacent to the mammary ducts and have a tendency to metastasize to regional lymph nodes and distant anatomical sites. In this chapter, only invasive carcinomas will be considered.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Recommended Reading
Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status and prognosis in patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–50. The authors evaluated the gene expression to determine the molecular subtype of breast cancer. Subsequently, the positive hormone receptor group was evaluated with a panel of four markers (Ki-67, HER2, estrogen receptor and progesterone receptor). The results showed that patients with positive receptors could be separated into two distinct groups (luminal A and luminal B) with repercussion on survival. The main contribution of this study was to demonstrate that these markers may be useful in separating the luminal A and luminal B groups similar to the molecular evaluation.
Hicks DG, Lester SC. Diagnostic pathology breast. 2nd ed. Canada: Amirsys/Elsevier; 2016. An excellent book in which the authors describe the main topics of mammary pathology. In the chapter about carcinoma, they correlate clinical and imaging findings with those of macroscopy. In addition, they also correlate microscopic, immunohistochemical and molecular findings with the prognosis and survival of patients with breast carcinomas.
Lakahni SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, editors. World Health Organization Classification of Tumours of the Breast. Lyon: IARC Press; 2012. This publication refers to the issue of the World Health Organization on classification of breast tumors and it reflects the views of the Consensus Group of breast cancer experts who met in September 2011 in Lyon, France. Among the invasive carcinomas, the alternative of using the term “invasive carcinoma” is proposed only in cases of breast carcinoma when they do not belong to a special subtype.
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–74. In a prospective study, the survival analysis of patients with locally advanced and uniformly treated breast disease showed significant differences for patients belonging to different molecular groups. The basal-simile group correlated with worse prognosis and there was a difference between the two positive receptor groups, with the luminal group A presenting a better prognosis than luminal group B.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Bacchi, C.E., Viana, C.R. (2019). Histopathological and Immunohistochemical Classification of Invasive Breast Carcinomas. In: Novita, G., Frasson, A., Millen, E., Zerwes, F., Cavalcante, F. (eds) Breast Diseases. Springer, Cham. https://doi.org/10.1007/978-3-030-13636-9_26
Download citation
DOI: https://doi.org/10.1007/978-3-030-13636-9_26
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-13635-2
Online ISBN: 978-3-030-13636-9
eBook Packages: MedicineMedicine (R0)